The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Pooled analysis of management of nausea and vomiting in patients treated with T-DXd
Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, comments on the incidence and management of nausea and vomiting in patients treated with trastuzumab deruxtecan (T-DXd). A pooled analysis of several clinical trials (DESTINY-Breast01, -Breast02, -Breast03, -Breast04, -Lung01, -Lung02; NCT03248492, NCT03523585, NCT03529110, NCT03734029, NCT03505710, NCT04644237, NCT02564900) in various tumor types, including metastatic low breast cancer, HER2+ gastric cancer, and HER2-mutant non-small cell lung cancer (NSCLC), revealed that a majority of patients experienced nausea and vomiting. Effective prophylaxis and management strategies are crucial for maintaining treatment adherence and duration. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role – AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding – AstraZeneca; Gencurix (Inst); Genome Insight (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses – Gilad
